Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome.
Aged
Carcinoma, Pancreatic Ductal
/ drug therapy
Deoxycytidine
/ analogs & derivatives
Enterobacteriaceae
/ isolation & purification
Female
Humans
Male
Microbiota
Middle Aged
Neoadjuvant Therapy
/ adverse effects
Paclitaxel
/ therapeutic use
Pancreatic Neoplasms
/ drug therapy
Stents
/ adverse effects
Tumor Microenvironment
Gemcitabine
Biliary stent
Microbiota
Neoadjuvant chemotherapy
Pancreatic adenocarcinoma
Pancreatic tumor microbiota
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
16 10 2021
16 10 2021
Historique:
received:
04
05
2021
accepted:
05
10
2021
entrez:
17
10
2021
pubmed:
18
10
2021
medline:
14
1
2022
Statut:
epublish
Résumé
Intra-tumor microbiota have been implicated in pancreatic ductal adenocarcinoma (PDAC) development, treatment response and post-treatment survivorship. Moreover, therapeutic interventions targeting microbiota may improve the response to chemotherapy and immunotherapy, further emphasizing the critical need to understand the origins of and growth of bacteria within the pancreatic tumor microenvironment. Here, we studied the role of several clinical factors on the bacterial colonization of PDAC. We obtained matched tumor and normal pancreatic tissue specimens from 27 patients who had undergone surgical resection for PDAC between 2011 and 2015 from the University of Minnesota Biological Materials Procurement Network (BioNet). We found that 26 (48%) out of 54 pancreatic tissue samples harbored detectable bacterial communities using real-time PCR targeting the 16S rRNA gene. Bacterial colonization was detected significantly more frequently in samples from patients who had pancreatic head tumors, underwent Whipple procedure, or had preoperative biliary stent placement. There was also a significantly greater relative abundance of microbiota from the family Enterobacteriaceae among samples from patients who underwent biliary stent placement or neoadjuvant treatment with a combination of Gemcitabine and Paclitaxel. These findings suggest that biliary stent placement and neoadjuvant chemotherapy are associated with specific alterations that promote the infiltration and growth of intra-tumor bacteria in the setting of PDAC. Further studies exploring whether specific bacterial communities could contribute to increased chemoresistance will be essential for optimizing medical therapies in the future.
Sections du résumé
BACKGROUND
Intra-tumor microbiota have been implicated in pancreatic ductal adenocarcinoma (PDAC) development, treatment response and post-treatment survivorship. Moreover, therapeutic interventions targeting microbiota may improve the response to chemotherapy and immunotherapy, further emphasizing the critical need to understand the origins of and growth of bacteria within the pancreatic tumor microenvironment. Here, we studied the role of several clinical factors on the bacterial colonization of PDAC.
RESULTS
We obtained matched tumor and normal pancreatic tissue specimens from 27 patients who had undergone surgical resection for PDAC between 2011 and 2015 from the University of Minnesota Biological Materials Procurement Network (BioNet). We found that 26 (48%) out of 54 pancreatic tissue samples harbored detectable bacterial communities using real-time PCR targeting the 16S rRNA gene. Bacterial colonization was detected significantly more frequently in samples from patients who had pancreatic head tumors, underwent Whipple procedure, or had preoperative biliary stent placement. There was also a significantly greater relative abundance of microbiota from the family Enterobacteriaceae among samples from patients who underwent biliary stent placement or neoadjuvant treatment with a combination of Gemcitabine and Paclitaxel.
CONCLUSIONS
These findings suggest that biliary stent placement and neoadjuvant chemotherapy are associated with specific alterations that promote the infiltration and growth of intra-tumor bacteria in the setting of PDAC. Further studies exploring whether specific bacterial communities could contribute to increased chemoresistance will be essential for optimizing medical therapies in the future.
Identifiants
pubmed: 34656097
doi: 10.1186/s12866-021-02339-3
pii: 10.1186/s12866-021-02339-3
pmc: PMC8520243
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Paclitaxel
P88XT4IS4D
Gemcitabine
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
280Subventions
Organisme : NCI NIH HHS
ID : 5P50CA101955-09
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Cell. 2019 Aug 8;178(4):795-806.e12
pubmed: 31398337
Gut. 2019 Jan;68(1):130-139
pubmed: 29158237
Clin Gastroenterol Hepatol. 2020 Nov 5;:
pubmed: 33161160
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Gut. 2018 Jan;67(1):120-127
pubmed: 27742762
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Br J Surg. 2017 Jan;104(2):e182-e188
pubmed: 28121036
Nucleic Acids Res. 2009 Jan;37(Database issue):D141-5
pubmed: 19004872
Crit Rev Oncol Hematol. 2019 Dec;144:102824
pubmed: 31731215
J Med Microbiol. 2018 Aug;67(8):1090-1095
pubmed: 29975626
Nat Biotechnol. 2016 Sep;34(9):942-9
pubmed: 27454739
Nature. 2019 Oct;574(7777):264-267
pubmed: 31578522
Cancer Discov. 2018 Apr;8(4):403-416
pubmed: 29567829
Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):370-383
pubmed: 30373903
Mol Cancer. 2019 May 20;18(1):97
pubmed: 31109338
Cancer Lett. 2013 Jul 28;335(2):447-54
pubmed: 23499889
ISME J. 2012 Aug;6(8):1621-4
pubmed: 22402401
Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):53-64
pubmed: 31811279
Mol Cell Oncol. 2017 Dec 11;5(1):e1405139
pubmed: 29404397
HPB (Oxford). 2019 Dec;21(12):1753-1760
pubmed: 31101398
Nucleic Acids Res. 2007;35(21):7188-96
pubmed: 17947321
Microbiome. 2018 Sep 18;6(1):166
pubmed: 30227892
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514451
Commun Biol. 2021 Aug 31;4(1):1019
pubmed: 34465850
Science. 2017 Sep 15;357(6356):1156-1160
pubmed: 28912244